Sarah Ejiama
| Sarah Ejiama | |
|---|---|
| Born | Sarah Nmanwayi Ejiama |
| 🏳️ Nationality | British |
| Other names | Sarah Nmanwayi Ede |
| 🎓 Alma mater | University of Exeter (BSc) University of Bath (MRes) |
| 💼 Occupation | |
Sarah Nmanwayi Ejiama MRes is a Research Assistant with the Molecular Oncology group of Richard Marais’ laboratory at the Cancer Research UK (CRUK) Manchester Institute, University of Manchester.[3] She’s also the founder and CEO of Brighter Connect, UK.[4]
Education[edit]
Ejiama studied at the University of Exeter where she was awarded a Bachelor of Science degree in Evolutionary Biology in 2011 supervised by David Hosken.[5] She completed her postgraduate study at the University of Bath where she was awarded a MRes in Regenerative Medicine in 2012 for research on Stem Cells supervised by Makoto Furutani-Seiki. [6]
Career and research[edit]
Ejiama started her career as a Research Assistant with Richard Marais’s laboratory at the Cancer Research UK (CRUK) Manchester Institute where she contributed to early research into Skin Cancer on Melanoma in Manchester in 2012.[7]
Her research work looked into the analysis of Melanoma and other Cancer cells providing integrated care opportunities for patients in the long-term.[8] Her work in 2014 on ‘Ultraviolet radiation accelerating BRAF-driven melanomagenesis by targeting TP53' informs the understanding in this clinical area with regards to Melanoma.[9][3][10][10][11] This study expressed BRAF in melanocytes of adolescent mice at physiologic levels mimicking the acquisition of mutation in humans. She also contributed to the research on paradox-breaking RAF inhibitors that also target SRC on how they are effective in drug resistant BRAF mutant Melanoma.[12][13][14]
Ejiama’s further research work with Richard Marais including others on why sunscreens do not fully protect against the development of Melanoma on mice helped to draw awareness on humans.[3][8] The study concluded that “sunscreen even with a sun protection factor (SPF) 50 may not fully protect against the development of Melanoma. Sunscreen protects against immediate radiation damage including sunburn; but the radiation can still penetrate and damage the DNA of cells and cause cancer, according to an animal study” [15]
References[edit]
- ↑ Girotti, Maria Romina; Lopes, Filipa; Preece, Natasha; Niculescu-Duvaz, Dan; Zambon, Alfonso; Davies, Lawrence; Whittaker, Steven; Saturno, Grazia; Viros, Amaya; Pedersen, Malin; Suijkerbuijk, Bart M.J.M.; Menard, Delphine; McLeary, Robert; Johnson, Louise; Fish, Laura; Ejiama, Sarah; Sanchez-Laorden, Berta; Hohloch, Juliane; Carragher, Neil; MacLeod, Kenneth; Ashton, Garry; Marusiak, Anna A.; Fusi, Alberto; Brognard, John; Frame, Margaret; Lorigan, Paul; Marais, Richard; Springer, Caroline (2015). "Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma" (PDF). Cancer Cell. 27: 85–96. doi:10.1016/j.ccell.2014.11.006. Unknown parameter
|s2cid=ignored (help) - ↑ Girotti, M. R.; Lopes, F.; Preece, N.; Niculescu-Duvaz, D.; Zambon, A.; Davies, L.; Whittaker, S.; Saturno, G.; Viros, A.; Pedersen, M.; Suijkerbuijk, B. M.; Menard, D.; McLeary, R.; Johnson, L.; Fish, L.; Ejiama, S.; Sanchez-Laorden, B.; Hohloch, J.; Carragher, N.; MacLeod, K.; Ashton, G.; Marusiak, A. A.; Fusi, A.; Brognard, J.; Frame, M.; Lorigan, P.; Marais, R.; Springer, C. (2016-08-23). "Europe PMC". Cancer Cell. Europe PMC. 31 (3): 466–. doi:10.1016/j.ccell.2017.02.007. PMC 6848950 Check
|pmc=value (help). PMID 28292443. - ↑ 3.0 3.1 3.2 Usandizaga, Amaya Viros; Sanchez-Laorde, Berta Lopez; Pedersen, Malin; Furney, Simon; Rae, Joel; Hogan, Kate; Ejiama, Sarah; Girotti, Romina; Cook, Martin; Dhomen, Nathalie; Marais, Richard (2014-06-11). "Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53". Nature. 511 (7510): 478–482. doi:10.1038/nature13298. PMC 4112218. PMID 24919155.
- ↑ "BRIGHTER CONNECT LIMITED :: United Kingdom :: OpenCorporates". opencorporates.com. Retrieved 2022-07-13.
- ↑ "Profile | Biosciences | University of Exeter". biosciences.exeter.ac.uk. Retrieved 2022-07-13.
- ↑ "CDB Symposium 2016". www.cdb.riken.jp. Retrieved 2022-07-13.
- ↑ Girotti, Maria R.; Lopes, Filipa; Preece, Natasha; Niculescu-Duvaz, Dan; Zambon, Alfonso; Davies, Lawrence; Whittaker, Steven; Saturno, Grazia; Viros, Amaya; Pedersen, Malin; Suijkerbuijk, Bart MJM (2014-10-01). "Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations". Cancer Research. 74 (19_Supplement): 3704. doi:10.1158/1538-7445.AM2014-3704. ISSN 0008-5472.
- ↑ 8.0 8.1 Viros, Amaya; Sanchez-Laorden, Berta; Pedersen, Malin; Furney, Simon J.; Rae, Joel; Hogan, Kate; Ejiama, Sarah; Girotti, Maria Romina; Cook, Martin; Dhomen, Nathalie; Marais, Richard (2014). "Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53". Nature. 511 (7510): 478–482. doi:10.1038/nature13298. PMC 4112218. PMID 24919155.
- ↑ "Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma". University of Edinburgh Research Explorer. Retrieved 2022-07-11.
- ↑ 10.0 10.1 Amaya Viros, Berta Sanchez-Laorden (2014-06-11). "Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53". Nature. 511 (7510): 478–482. doi:10.1038/nature13298. PMC 4112218. PMID 24919155. Retrieved 2022-07-11.
- ↑ "Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53". read.qxmd.com. Retrieved 2022-07-11.
- ↑ Girotti, Maria Romina; Lopes, Filipa; Preece, Natasha; Niculescu-Duvaz, Dan; Zambon, Alfonso; Davies, Lawrence O.; Whittaker, Steven; Saturno, Grazia; Viros, Amaya; Pedersen, Malin; Suijkerbuijk, Bart M. J. M. (2015-02-12). "Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma". Cancer Cell. 27 (1): 85–96. doi:10.1016/j.ccell.2014.11.006. ISSN 1878-3686. PMC 4297292. PMID 25500121.
- ↑ Girotti, Maria Romina; Lopes, Filipa; Preece, Natasha; Niculescu-Duvaz, Dan; Zambon, Alfonso; Davies, Lawrence; Whittaker, Steven; Saturno, Grazia; Viros, Amaya; Pedersen, Malin; Suijkerbuijk, Bart M. J. M. (2017-03-13). "Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma". Cancer Cell. 31 (3): 466. doi:10.1016/j.ccell.2017.02.007. ISSN 1878-3686. PMC 6848950 Check
|pmc=value (help). PMID 28292443. - ↑ Girotti, Maria Romina; Lopes, Filipa; Preece, Natasha; Niculescu-Duvaz, Dan; Zambon, Alfonso; Davies, Lawrence; Whittaker, Steven; Saturno, Grazia; Viros, Amaya; Pedersen, Malin; Suijkerbuijk, Bart M. J. M. (2014). "Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma". Cancer Cell. 27 (1).
- ↑ "Sunscreens do not fully protect against the development of melanoma, mouse study suggests". ScienceDaily. Retrieved 2022-07-11.
This article "Sarah Ejiama" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Sarah Ejiama. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
